We are grateful to the NIH (GM079339) and the NSF
(CAREER Award to J.W.B.) for support of this research.
P.C.C. received a fellowship from the government of Taiwan.
Unrestricted support from Bristol Myers Squibb and Roche is
gratefully acknowledged.
Notes and references
1 J. W. Bode, Curr. Opin. Drug Discovery Dev., 2006, 9, 765–775.
2 (a) T. Maki, K. Ishihara and H. Yamamoto, Tetrahedron, 2007, 63,
8645–8657; (b) K. Ishihara, S. Ohara and H. Yamamoto, J. Org.
Chem., 1996, 61, 4196–4197; (c) R. M. Al-Zoubi, O. Marion and
D. G. Hall, Angew. Chem., Int. Ed., 2008, 47, 2876–2879.
3 (a) C. Gunanathan, Y. Ben-David and D. Milstein, Science, 2007,
317, 790–792; (b) T. Zweifel, J.-V. Naubron and H. Grutzmacher,
Angew. Chem., Int. Ed., 2009, 48, 559–563; (c) L. U. Nordstrøm,
H. Vogt and R. Madsen, J. Am. Chem. Soc., 2008, 130,
17672–17673.
4 C. P. R. Hackenberger and D. Schwarzer, Angew. Chem., Int. Ed.,
2008, 47, 10030–10074.
5 J. W. Bode, R. M. Fox and K. D. Baucom, Angew. Chem., Int. Ed.,
2006, 45, 1248–1252.
6 For a highlight, see: K. Zeitler, Angew. Chem., Int. Ed., 2005,
44, 7506–7510.
7 D. Enders, O. Niemeier and A. Henseler, Chem. Rev., 2007, 107,
5606–5655.
8 K. Y.-K. Chow and J. W. Bode, J. Am. Chem. Soc., 2004, 126,
8126–8127.
9 (a) N. T. Reynolds, J. Read de Alaniz and T. Rovis, J. Am. Chem.
Soc., 2004, 126, 9518–9519; (b) N. T. Reynolds and T. Rovis,
J. Am. Chem. Soc., 2005, 127, 16406–16407.
10 S. S. Sohn and J. W. Bode, Angew. Chem., Int. Ed., 2006, 45,
6021–6024.
11 (a) S. S. Sohn, E. L. Rosen and J. W. Bode, J. Am. Chem. Soc.,
2004, 126, 14370–14371; (b) S. S. Sohn and J. W. Bode, Org. Lett.,
2005, 7, 3873–3876; (c) A. Chan and K. A. Scheidt, Org. Lett.,
2005, 7, 905–908.
12 (a) H. U. Vora and T. Rovis, J. Am. Chem. Soc., 2007, 129,
13796–13797; (b) J. W. Bode and S. S. Sohn, J. Am. Chem. Soc.,
2007, 129, 13798–13799.
13 P.-C. Chiang, M. Rommel and J. W. Bode, J. Am. Chem. Soc.,
2009, 131, 8714–8718.
14 (a) C. Palomo, M. Oiarbide, J. M. Garcıa, A. Gonzalez and
E. Arceo, J. Am. Chem. Soc., 2003, 125, 13942–13943;
(b) M. Reiter, H. Turner, R. Mills-Webb and V. Gouverneur,
J. Org. Chem., 2005, 70, 8478–8485.
15 For an improved protocol and a survey of other methods for the
synthesis of a,b-unsaturated aldehydes, see: P. Valenta,
N. A. Drucker, J. W. Bode and P. J. Walsh, Org. Lett., 2009, 11,
2117–2119.
Scheme 1 Postulated tandem catalytic cycles for amide formation
from a0-hydroxyenones.
compounds. With 10 mol% 1,2,4-triazole, however, the
desired amides were chemoselectively formed in moderate to
good yield.
We believe that this NHC-catalyzed redox amidation
proceeds according to the tandem catalytic cycle shown
in Scheme 1. Attack of the NHC-catalyst onto the
a0-hydroxyenone gives I, which expels acetone to generate
Breslow intermediate II. The conjugate acid of the catalytic
base, formed during the deprotonation of the triazolium
precatalyst, protonates the Breslow intermediate, which may be
considered as a formal homoenolate equivalent. Tautomerization
of III affords activated carboxylate IV. This intermediate is a
competent acylating agent for alcohols, but reacts only slowly
with amines and is turned over by the triazole co-catalyst to
regenerate the precatalyst and form acyl triazole V. This is the
active acylating agent with amines.20
16 In some cases, modest yields (5–30%) of amide products could be
obtained without a co-catalyst. For many substrates, however, no
amide products were obtained in the absence of 1,2,4-triazole or
similar promoter.
17 During the course of this work, Birman reported that the combi-
nation of 1,2,4-triazole and base catalyzes the acylations of amines
and esters: X. Yang and V. B. Birman, Org. Lett., 2009, 11,
1499–1502.
In summary, we have documented a new method for
catalytic amide formation. No stoichiometric reagents are
required, the reaction proceeds under mild conditions, and
the only byproduct is one equivalent of acetone. The use of
readily prepared a0-hydroxyenones overcomes the two major
limitations of a,b-unsaturated aldehydes as substrates in
similar amidation reactions: (1) their relative difficulty of
preparation and (2) their tendency to form imines that
complicate the reaction protocols or contaminate the desired
amide product. The two distinct catalytic cycles involved in
this reaction offer the opportunity to develop new chemo- and
stereoselective processes for amine acylation.
18 This triazolium precatalyst is commercially available from Aldrich
(Cat. No. 688487).
19 M. Movassaghi and M. A. Schmidt, Org. Lett., 2005, 7,
2453–2456.
20 We have detected this intermediate during the reaction and studied it
1
by H NMR and 13C NMR. This data supports the regiochemical
assignment shown in Scheme 1.
ꢀc
This journal is The Royal Society of Chemistry 2009
4568 | Chem. Commun., 2009, 4566–4568